Trial Profile
ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms ZENO-01
- 27 Mar 2014 New trial record